Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 16INDUSTRY 3NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Waldenstrom Macroglobulinemia 3Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Rituximab 23Cyclophosphamide 17Bortezomib 15Filgrastim 14Peripheral Blood Stem Cell Transplantation 13fludarabine phosphate 10Etoposide 10Vincristine 8Radiotherapy 8Cyclosporine 8tanespimycin 7Prednisone 7alvocidib 6Vorinostat 6Ifosfamide 6Doxorubicin 6Cytarabine 6Melphalan 5Lenalidomide 5Busulfan 5temsirolimus 4sargramostim 4bryostatin 1 4Paclitaxel 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interferon-alpha 4Gemcitabine 4Dexamethasone 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lymphoma, Mantle-Cell × ibritumomab tiuxetan × Clear all
NCT00070447 2014-01-28

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Completed
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

NCT00017381 2013-01-09

Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Completed
30 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡